Nurix Therapeutics Net Worth
Nurix Therapeutics Net Worth Breakdown | NRIX |
Nurix Therapeutics Net Worth Analysis
Nurix Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Nurix Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Nurix Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Nurix Therapeutics' net worth analysis. One common approach is to calculate Nurix Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Nurix Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Nurix Therapeutics' net worth. This approach calculates the present value of Nurix Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Nurix Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Nurix Therapeutics' net worth. This involves comparing Nurix Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Nurix Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Nurix Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Nurix Therapeutics' net worth research are outlined below:
| Nurix Therapeutics generated a negative expected return over the last 90 days | |
| Nurix Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 76.99 M. Net Loss for the year was (143.95 M) with loss before overhead, payroll, taxes, and interest of (145.87 M). | |
| Nurix Therapeutics currently holds about 344.48 M in cash with (81.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.31. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference |
Nurix Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Nurix Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Nurix Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 11th of April 2024 Next Financial Report | View | |
| 30th of November 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 31st of August 2023 Last Quarter Report | View | |
| 30th of November 2022 Last Financial Announcement | View |
Know Nurix Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Nurix Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Nurix Therapeutics backward and forwards among themselves. Nurix Therapeutics' institutional investor refers to the entity that pools money to purchase Nurix Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Soleus Capital Management, L.p. | 2024-06-30 | 2.1 M | Commodore Capital Lp | 2024-09-30 | 1.6 M | Citadel Advisors Llc | 2024-09-30 | 1.5 M | Geode Capital Management, Llc | 2024-09-30 | 1.4 M | Driehaus Capital Management Llc | 2024-06-30 | 1.3 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.2 M | Candriam Luxembourg S.c.a. | 2024-06-30 | 1.2 M | Deutsche Bank Ag | 2024-06-30 | 1 M | Nuveen Asset Management, Llc | 2024-06-30 | 981.2 K | Blackrock Inc | 2024-06-30 | 6.8 M | Redmile Group, Llc | 2024-09-30 | 4.3 M |
Follow Nurix Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.5 B.Market Cap |
|
Project Nurix Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.47) | (0.49) | |
| Return On Capital Employed | (0.52) | (0.55) | |
| Return On Assets | (0.47) | (0.49) | |
| Return On Equity | (0.83) | (0.78) |
When accessing Nurix Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Nurix Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Nurix Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Nurix Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Nurix Therapeutics. Check Nurix Therapeutics' Beneish M Score to see the likelihood of Nurix Therapeutics' management manipulating its earnings.
Evaluate Nurix Therapeutics' management efficiency
Nurix Therapeutics has return on total asset (ROA) of (0.2946) % which means that it has lost $0.2946 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5796) %, meaning that it created substantial loss on money invested by shareholders. Nurix Therapeutics' management efficiency ratios could be used to measure how well Nurix Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.49 in 2024. Return On Capital Employed is likely to drop to -0.55 in 2024. At this time, Nurix Therapeutics' Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 5.7 M in 2024, whereas Total Assets are likely to drop slightly above 318.1 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.32 | 4.35 | |
| Tangible Book Value Per Share | 3.32 | 4.38 | |
| Enterprise Value Over EBITDA | (2.00) | (2.10) | |
| Price Book Value Ratio | 1.52 | 1.59 | |
| Enterprise Value Multiple | (2.00) | (2.10) | |
| Price Fair Value | 1.52 | 1.59 | |
| Enterprise Value | 282.6 M | 475.4 M |
The operational strategies employed by Nurix Therapeutics management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 19.193 | Revenue 56.4 M | Quarterly Revenue Growth (0.32) | Revenue Per Share 0.922 | Return On Equity (0.58) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nurix Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nurix Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nurix Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nurix Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 4th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 31st of October 2024 Other Reports | ViewVerify |
Nurix Therapeutics Earnings per Share Projection vs Actual
Nurix Therapeutics Corporate Management
| Stefani Wolff | COO Devel | Profile | |
| Christine JD | Secretary Officer | Profile | |
| John Kuriyan | Founder Board | Profile | |
| JD Esq | VP Counsel | Profile | |
| Cristiana Guiducci | Senior Research | Profile | |
| Pasit Phiasivongsa | Chief Officer | Profile |
Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.